TABLE 3.
Overall daily doses of MMF and monitoring of MPA levels during follow-up.
| MMF dose (mg/d) | Pre-MMF-MT (CNI-MMF) | MMF-MT (3-mo) | MMF-MT (6-mo) | MMF-MT (12-mo) | a MMF-MT (median: 78-mo) (last outpatient review) |
|---|---|---|---|---|---|
| 500 | 8 (2.5%) | 4 (1.2%) | 2 (0.6%) | 7 (2.2%) | 7 (2.2%) |
| 750 | 3 (0.9%) | 4 (1.2%) | 4 (1.2%) | 8 (2.5%) | 18 (5.6%) |
| 1,000 | 101 (31.2%) | 54 (16.7%) | 47 (14.5%) | 51 (15.7%) | 110 (33.9%) |
| 1,250 | 4 (1.2%) | 15 (4.6%) | 13 (4%) | 20 (6.2%) | 15 (4.6%) |
| 1,500 | 68 (20.9%) | 89 (27.5%) | 78 (24.1%) | 86 (26.5%) | 60 (18.5%) |
| 1,750 | 3 (0.9%) | 11 (3.4%) | 13 (4%) | 12 (3.7%) | 4 (1.2%) |
| 2,000 | 100 (30.9%) | 130 (40.1%) | 139 (42.9%) | 109 (33.6%) | 99 (30.6%) |
| N/A | 37 (11.4%) | 17 (5.2%) | 28 (8.6%) | 31 (9.6%) | 11 (3.4%) |
| MPA median levels (ng/mL) | 2.6 (0.1–15) | 3.3 (0.4–13) | 3.3 (0.5–12) | 3 (0.5–19) | 2.7 (0.2–15) |
a
Comparison between MPA levels in the pre-MMF-MT period and the last outpatient visit (p = 0.527). CNI, calcineurin inhibitor; MMF-MT, mycophenolate mofetil monotherapy; MPA, mycophenolic acid.